CE Mark awarded to anti-CCP diagnostic kit
A diagnostic kit for rheumatoid arthritis has been given a CE Mark.
An anti-cyclic citrullinated peptides (anti-CCP) diagnostic kit for rheumatoid arthritis has been given the CE Mark of approval, Theradiag announced today (April 23rd).
This in-vitro test adds to the theranostic specialist's Fidis portfolio of equipment for auto-immunes diseases, with the technology expected to bring down the time and cost of analysis.
According to the company, this new method of uncovering anti-CCP antibodies provides a reliable detection of severe forms of rheumatoid arthritis at more rapid dosing and at a lower price than existing equipment.
It marks the third proprietary diagnostic kit of Theradiag to be offered a CE Mark this year, with the auto-immune diseases segment growing in 2012 and sparking a 17 per cent increase for its Fidis products.
"With this new addition to the Fidis range we position ourselves as testing and monitoring leaders in auto-immune and inflammatory diseases," said Michel Finance, chief executive of Theradiag.
A statement from the company revealed the auto-immune diseases segment made up 43 per cent of its total company sales last year.
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance